Rigel Pharmaceuticals (RIGL) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic objectives and business evolution

• Four strategic objectives: grow commercial business, in-license/add products, advance pipeline, maintain financial discipline.

• Transitioned from a single-product company in 2020 to three commercial products and four indications by 2025.

• Achieved profitability in Q3 2024, generating $100 million in cash since then.

• Plans to continue growth through 2030 by expanding the portfolio and advancing R289.

• Sales grew 35% from 2022 to 2025, with a 41% year-over-year increase in Q4 2025.

Commercial product performance

• TAVALISSE sales reached $45 million, with 47% growth and expanded use in earlier treatment lines.

• GAVRETO sales increased from $7 million to over $10 million per quarter after acquisition.

• REZLIDHIA, launched for relapsed/refractory IDH1+ AML, grew to nearly $10 million per quarter.

• Inflation Reduction Act improved patient retention for TAVALISSE, smoothing revenue across quarters.

• International partnerships drive additional revenue and market expansion.

Pipeline and R&D focus

• R289 (IRAK1/4 inhibitor) is the lead pipeline asset, targeting low-risk MDS with promising early data.

• Phase 1b study showed 33% response in heavily pretreated, transfusion-dependent patients at adequate doses.

• Dose expansion phase ongoing; registrational study planned for 2027.

• Exploring additional indications for R289, leveraging its unique mechanism and first-mover advantage.

• Collaborations with MD Anderson, MyeloMATCH, and others to expand clinical data and indications.